Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies
暂无分享,去创建一个
O. Elemento | W. Du | W Du | O Elemento
[1] Jae-Hyun Park,et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. , 2012, Cancer cell.
[2] Gary D Bader,et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types , 2013, Scientific Reports.
[3] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[4] Tilman Brummer,et al. Feedback regulation of lymphocyte signalling , 2004, Nature Reviews Immunology.
[5] Eli Upfal,et al. Algorithms for Detecting Significantly Mutated Pathways in Cancer , 2010, RECOMB.
[6] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[7] Ali Bashashati,et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling , 2013, The Journal of pathology.
[8] Lee T. Sam,et al. Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.
[9] N. Forbes,et al. Mechanistic modelling of dynamic MRI data predicts that tumour heterogeneity decreases therapeutic response , 2010, British Journal of Cancer.
[10] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[11] Frank McCormick,et al. The molecular pathology of cancer , 2010, Nature Reviews Clinical Oncology.
[12] Tom Misteli,et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.
[13] Daniel C Kirouac,et al. Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors , 2013, Science Signaling.
[14] Yan Zhang,et al. Optical imaging of tumor microenvironment. , 2013, American journal of nuclear medicine and molecular imaging.
[15] B. Ross,et al. Mathematical Modeling of PDGF-Driven Glioblastoma Reveals Optimized Radiation Dosing Schedules , 2014, Cell.
[16] Nci Dream Community. A community effort to assess and improve drug sensitivity prediction algorithms , 2014 .
[17] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[18] S. Fuqua,et al. RNA sequencing of cancer reveals novel splicing alterations , 2013, Scientific Reports.
[19] Dennis C. Friedrich,et al. Whole-exome sequencing and clinical interpretation of formalin-fixed , paraffin-embedded tumor samples to guide precision cancer medicine , 2014 .
[20] P. Jänne,et al. The quest to overcome resistance to EGFR-targeted therapies in cancer , 2013, Nature Medicine.
[21] Huanming Yang,et al. Single-Cell Exome Sequencing Reveals Single-Nucleotide Mutation Characteristics of a Kidney Tumor , 2012, Cell.
[22] David Haussler,et al. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM , 2010, Bioinform..
[23] Lee T. Sam,et al. Transcriptome Sequencing to Detect Gene Fusions in Cancer , 2009, Nature.
[24] S. Horvath,et al. Global histone modification patterns predict risk of prostate cancer recurrence , 2005, Nature.
[25] M. Ehrlich,et al. DNA methylation in cancer: too much, but also too little , 2002, Oncogene.
[26] Elise C. Kohn,et al. The microenvironment of the tumour–host interface , 2001, Nature.
[27] M. Koch,et al. Tumour-site-dependent expression profile of angiogenic factors in tumour-associated stroma of primary colorectal cancer and metastases , 2013, British Journal of Cancer.
[28] Chris Sander,et al. Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.
[29] T. Eberlein,et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .
[30] D. Vitkup,et al. Heterogeneity of tumor-induced gene expression changes in the human metabolic network , 2013, Nature Biotechnology.
[31] Gavin MacBeath,et al. Receptor Tyrosine Kinases Fall into Distinct Classes Based on Their Inferred Signaling Networks , 2013, Science Signaling.
[32] G. Parmigiani,et al. The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.
[33] D. Quail,et al. Microenvironmental regulation of tumor progression and metastasis , 2014 .
[34] Alison P. Klein,et al. Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene , 2009, Science.
[35] Benjamin J Vakoc,et al. Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging , 2009, Nature Medicine.
[36] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[37] Adam A. Margolin,et al. Systematic Analysis of Challenge-Driven Improvements in Molecular Prognostic Models for Breast Cancer , 2013, Science Translational Medicine.
[38] Luay Nakhleh,et al. Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling , 2011, Oncogene.
[39] Bertram Klinger,et al. Supplementary Materials for : Network quantification of EGFR signaling unveils potential for targeted combination therapy , 2022 .
[40] L. Tanoue. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR , 2011 .
[41] Tai-Hsien Ou Yang,et al. Development of a Prognostic Model for Breast Cancer Survival in an Open Challenge Environment , 2013, Science Translational Medicine.
[42] K. Vousden,et al. p53 mutations in cancer , 2013, Nature Cell Biology.
[43] A. Sivachenko,et al. Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.
[44] Zohar Mukamel,et al. Epigenetic polymorphism and the stochastic formation of differentially methylated regions in normal and cancerous tissues , 2012, Nature Genetics.
[45] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[46] Pradeep S Rajendran,et al. Single-cell dissection of transcriptional heterogeneity in human colon tumors , 2011, Nature Biotechnology.
[47] Olivier Elemento,et al. A Panel of Four miRNAs Accurately Differentiates Malignant from Benign Indeterminate Thyroid Lesions on Fine Needle Aspiration , 2012, Clinical Cancer Research.
[48] Laura M. Heiser,et al. A community effort to assess and improve drug sensitivity prediction algorithms , 2014, Nature Biotechnology.
[49] M. Metzker. Sequencing technologies — the next generation , 2010, Nature Reviews Genetics.
[50] S. Balasubramanian,et al. Quantitative Sequencing of 5-Methylcytosine and 5-Hydroxymethylcytosine at Single-Base Resolution , 2012, Science.
[51] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[52] Brian J. Stevenson,et al. Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. , 2012, Genome research.
[53] Gabriel S. Eichler,et al. Signal pathway profiling of epithelial and stromal compartments of colonic carcinoma reveals epithelial-mesenchymal transition , 2008, Oncogene.
[54] E. Lengyel,et al. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra‐cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum , 2007, International journal of cancer.
[55] A. Sparks,et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient , 2010, Nature.
[56] Jonathan R. Karr,et al. A Whole-Cell Computational Model Predicts Phenotype from Genotype , 2012, Cell.
[57] B. Bernstein,et al. Epigenetic Reprogramming in Cancer , 2013, Science.
[58] M. Mann,et al. Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks , 2006, Cell.
[59] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[60] W. Sellers,et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition , 2009, Proceedings of the National Academy of Sciences.
[61] Liliana Florea,et al. Transcriptomic landscape of breast cancers through mRNA sequencing , 2012, Scientific Reports.
[62] Lee T. Sam,et al. Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. , 2011, Genome research.
[63] H. Burstein,et al. The distinctive nature of HER2-positive breast cancers. , 2005, The New England journal of medicine.
[64] A. Feinberg,et al. Increased methylation variation in epigenetic domains across cancer types , 2011, Nature Genetics.
[65] Juri G. Gelovani,et al. Methodological and practical challenges for personalized cancer therapies , 2011, Nature Reviews Clinical Oncology.
[66] J. Pollard. Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.
[67] Robert J Dempsey,et al. Science Times , 2022 .
[68] L. Chin,et al. Passenger Deletions Generate Therapeutic Vulnerabilities in Cancer , 2012, Nature.
[69] Marc Vidal,et al. COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation , 2010, Nature.
[70] K. Anderson,et al. Genetic variegation of clonal architecture and propagating cells in leukaemia , 2011, Nature.
[71] Amy E. Hawkins,et al. DNA sequencing of a cytogenetically normal acute myeloid leukemia genome , 2008, Nature.
[72] O. Elemento,et al. Epigenomic Evolution In Diffuse Large B-Cell Lymphomas , 2013 .
[73] Shamil R. Sunyaev,et al. Impact of deleterious passenger mutations on cancer progression , 2012, Proceedings of the National Academy of Sciences.
[74] F. Pépin,et al. Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.
[75] Steven J. M. Jones,et al. Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.
[76] Michael A. Davies,et al. Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents , 2012, Clinical Cancer Research.
[77] Trevor J Pugh,et al. Landscape of genomic alterations in cervical carcinomas , 2013, Nature.
[78] Steven J. M. Jones,et al. Integrated genomic characterization of endometrial carcinoma , 2013, Nature.
[79] Steven J. M. Jones,et al. Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.
[80] R. Arceci. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing , 2012 .
[81] Jeffrey T. Chang,et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.
[82] A. Ashworth,et al. Genetic Interactions in Cancer Progression and Treatment , 2011, Cell.
[83] David Basanta,et al. Exploiting evolution to treat drug resistance: combination therapy and the double bind. , 2011, Molecular pharmaceutics.
[84] R. Deberardinis,et al. A nanoparticle-based strategy for the imaging of a broad range of tumours by nonlinear amplification of microenvironment signals , 2013 .
[85] S. Huijben,et al. Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria model , 2007, Proceedings of the National Academy of Sciences.
[86] Z. Ling,et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation , 2013, Oncogene.
[87] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[88] P. A. Futreal,et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing , 2014, Nature Genetics.
[89] Alex M. Fichtenholtz,et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.
[90] Neil F. Johnson,et al. Model for in vivo progression of tumors based on co-evolving cell population and vasculature , 2011, Scientific reports.
[91] J. Troge,et al. Tumour evolution inferred by single-cell sequencing , 2011, Nature.
[92] H. Woo,et al. Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis , 2011, Proceedings of the National Academy of Sciences.
[93] Huanming Yang,et al. Single-Cell Exome Sequencing and Monoclonal Evolution of a JAK2-Negative Myeloproliferative Neoplasm , 2012, Cell.
[94] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[95] A. McKenna,et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. , 2014, Cancer cell.
[96] K. Polyak,et al. Intra-tumour heterogeneity: a looking glass for cancer? , 2012, Nature Reviews Cancer.
[97] Joshua F. McMichael,et al. Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.
[98] Sean C. Bendall,et al. Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum , 2011, Science.
[99] A. Balmain,et al. TGF-beta signaling in tumor suppression and cancer progression. , 2001, Nature genetics.
[100] Steven P Gygi,et al. Akt–RSK–S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases , 2010, Science Signaling.
[101] Andrew M. K. Brown,et al. Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer , 2013, Science.
[102] O. Abdel-Wahab,et al. The role of mutations in epigenetic regulators in myeloid malignancies , 2012, Nature Reviews Cancer.
[103] Uri Alon,et al. Predicting and controlling the reactivity of immune cell populations against cancer , 2009, Molecular systems biology.
[104] N. Carter,et al. Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development , 2011, Cell.
[105] P. Laird,et al. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina–associated domains , 2011, Nature Genetics.
[106] M. Roizen,et al. Hallmarks of Cancer: The Next Generation , 2012 .
[107] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[108] E. Petricoin,et al. Application of molecular technologies for phosphoproteomic analysis of clinical samples , 2014, Oncogene.
[109] A. Butte,et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. , 2013, Cancer discovery.
[110] Igor Goryanin,et al. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. , 2009, Cancer research.
[111] Jong-Soo Lee,et al. Interplay between Epigenetics and Genetics in Cancer , 2013, Genomics & informatics.
[112] M. Wigler,et al. PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.
[113] T. Gilmer,et al. Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations , 2012, Molecular Cancer Therapeutics.
[114] S. Joel,et al. Kinase-Substrate Enrichment Analysis Provides Insights into the Heterogeneity of Signaling Pathway Activation in Leukemia Cells , 2013, Science Signaling.
[115] C. Lewis,et al. Macrophage regulation of tumor responses to anticancer therapies. , 2013, Cancer cell.
[116] Andrew Menzies,et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.
[117] Jeff Gore,et al. Turning ecology and evolution against cancer , 2014, Nature Reviews Cancer.
[118] Robin L. Jones,et al. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. , 2014, Cell reports.
[119] K. Kinzler,et al. Cancer genes and the pathways they control , 2004, Nature Medicine.
[120] Mariano J. Alvarez,et al. Genome-wide Identification of Post-translational Modulators of Transcription Factor Activity in Human B-Cells , 2009, Nature Biotechnology.
[121] S. Nishizuka,et al. Reverse-phase protein lysate microarrays for cell signaling analysis , 2008, Nature Protocols.
[122] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[123] T. Golub,et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.
[124] Carlo C. Maley,et al. Clonal evolution in cancer , 2012, Nature.
[125] Marc Hafner,et al. Profiles of Basal and Stimulated Receptor Signaling Networks Predict Drug Response in Breast Cancer Lines , 2013, Science Signaling.
[126] Yang Kuang,et al. Tumor-Immune Interaction, Surgical Treatment, and Cancer Recurrence in a Mathematical Model of Melanoma , 2009, PLoS Comput. Biol..
[127] T. Fennell,et al. Melanoma genome sequencing reveals frequent PREX2 mutations , 2012, Nature.
[128] Adrian Wiestner,et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[129] Yao Lu,et al. In silico Experimentation of Glioma Microenvironment Development and Anti-tumor Therapy , 2012, PLoS Comput. Biol..
[130] Baran D. Sumer,et al. A Broad Nanoparticle-Based Strategy for Tumor Imaging by Nonlinear Amplification of Microenvironment Signals , 2013, Nature materials.
[131] T. Halazonetis,et al. Genomic instability — an evolving hallmark of cancer , 2010, Nature Reviews Molecular Cell Biology.
[132] Adam Kiezun,et al. Whole-exome sequencing and clinical interpretation of FFPE tumor samples to guide precision cancer medicine , 2013, Nature Medicine.
[133] P. A. Futreal,et al. Genome-Wide Mutational Signatures of Aristolochic Acid and Its Application as a Screening Tool , 2013, Science Translational Medicine.
[134] S. Gestl,et al. Tumor cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers , 2014, Nature.
[135] P. Nowell. The clonal evolution of tumor cell populations. , 1976, Science.
[136] D. Cheresh,et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. , 2012, Cancer cell.
[137] Masahiro Inoue,et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.
[138] A. McKenna,et al. Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.
[139] T. Wolfsberg,et al. DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status , 2008, Leukemia.
[140] V. P. Collins,et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics , 2013, Proceedings of the National Academy of Sciences.
[141] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[142] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[143] S. Fuqua,et al. Novel Insights into Breast Cancer Genetic Variance through RNA Sequencing , 2013, Scientific Reports.